Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Total Valuation
Repare Therapeutics has a market cap or net worth of $56.54M. The enterprise value is -$95.17M.
Market Cap$56.54M
Enterprise Value-$95.17M
Share Statistics
Repare Therapeutics has 42,510,708 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,510,708
Owned by Insiders1.68%
Owned by Institutions66.74%
Financial Efficiency
Repare Therapeutics’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -62.16%.
Return on Equity (ROE)-0.56
Return on Assets (ROA)-0.48
Return on Invested Capital (ROIC)-62.16%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee414.55K
Profits Per Employee-656.50K
Employee Count129
Asset Turnover0.30
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Repare Therapeutics is -0.66. Repare Therapeutics’s PEG ratio is 0.06.
PE Ratio-0.66
PS Ratio0.89
PB Ratio0.37
Price to Fair Value0.37
Price to FCF-0.73
Price to Operating Cash Flow-0.73
PEG Ratio0.06
Income Statement
In the last 12 months, Repare Therapeutics had revenue of 53.48M and earned -84.69M in profits. Earnings per share was -2.00.
Revenue53.48M
Gross Profit53.48M
Operating Income-93.52M
Pretax Income-83.25M
Net Income-84.69M
EBITDA-90.22M
Earnings Per Share (EPS)-2.00
Cash Flow
In the last 12 months, operating cash flow was -76.44M and capital expenditures 0.00, giving a free cash flow of -76.44M billion.
Operating Cash Flow-76.44M
Free Cash Flow-76.44M
Free Cash Flow per Share-1.80
Dividends & Yields
Repare Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change-58.44%
50-Day Moving Average1.14
200-Day Moving Average2.38
Relative Strength Index (RSI)65.72
Average Volume (3m)405.39K
Important Dates
Repare Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 3, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Repare Therapeutics as a current ratio of 6.77, with Debt / Equity ratio of 1.28%
Current Ratio6.77
Quick Ratio6.77
Debt to Market Cap0.03
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Repare Therapeutics has paid 1.44M in taxes.
Income Tax1.44M
Effective Tax Rate-0.02
Enterprise Valuation
Repare Therapeutics EV to EBITDA ratio is 0.30, with an EV/FCF ratio of 0.36.
EV to Sales-0.51
EV to EBITDA0.30
EV to Free Cash Flow0.36
EV to Operating Cash Flow0.36
Balance Sheet
Repare Therapeutics has $152.79M in cash and marketable securities with $1.93M in debt, giving a net cash position of -$150.86M billion.
Cash & Marketable Securities$152.79M
Total Debt$1.93M
Net Cash-$150.86M
Net Cash Per Share-$3.55
Tangible Book Value Per Share$3.56
Margins
Gross margin is 98.15%, with operating margin of -174.88%, and net profit margin of -158.37%.
Gross Margin98.15%
Operating Margin-174.88%
Pretax Margin-155.67%
Net Profit Margin-158.37%
EBITDA Margin-168.71%
EBIT Margin-172.31%
Analyst Forecast
The average price target for Repare Therapeutics is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside290.62% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast4.58%
EPS Growth Forecast10.59%